Morgan Stanley analyst Michael Ulz lowered the firm’s price target on Akero Therapeutics (AKRO) to $90 from $96 and keeps an Overweight rating on the shares. The company’s Q4 report was “uneventful” while execution across the Phase 3 SYNCHRONY program continues, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKRO:
- Akero Therapeutics: Buy Rating Backed by Groundbreaking Clinical Results and Strong Financial Position
- Akero Therapeutics Reports Promising Clinical Trial Results
- Akero Therapeutics: Strong Financial Health and Promising Clinical Trial Results Drive Buy Rating
- Biotech Alert: Searches spiking for these stocks today
- Akero Therapeutics reports Q4 EPS (99c), consensus ($1.12)